Safety and regulation at the leading edge of biomedical biotechnology

被引:5
作者
CohenHaguenauer, O [1 ]
机构
[1] HOP ST LOUIS 1, INST HEMATOL, LAB TRANSFERT GENET & ONCOL MOL, F-75475 PARIS 10, FRANCE
基金
美国国家科学基金会;
关键词
D O I
10.1016/S0958-1669(96)80027-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
[No abstract available]
引用
收藏
页码:265 / 272
页数:8
相关论文
共 53 条
[1]   BIG CHANGES AT THE RAC [J].
ANDERSON, WF .
HUMAN GENE THERAPY, 1994, 5 (11) :1309-1310
[2]  
[Anonymous], 1990, Hum Gene Ther, V1, P93
[3]   HUMAN SOMATIC GENE-THERAPY - PROGRESS AND PROBLEMS [J].
BRENNER, MK .
JOURNAL OF INTERNAL MEDICINE, 1995, 237 (03) :229-239
[4]   OVERVIEW OF REGULATION OF GENE-THERAPY IN EUROPE - A CURRENT STATEMENT INCLUDING REFERENCE TO US REGULATION [J].
COHENHAGUENAUER, O .
HUMAN GENE THERAPY, 1995, 6 (06) :773-785
[5]  
*COMM EUR COMM, 1987, PROD QUAL CONTR MED
[6]  
*COMM EUR COMM, 1990, PROD QUAL CONTR CYT
[7]  
*COMM EUR COMM, 1993, GEN THER INF NOT SEP
[8]  
*COMM EUR COMM, 1991, 91356EEC EUR COMM
[9]  
*COMM EUR COMM, 1991, GUID MIN RISK TRANSM
[10]  
*COMM EUR COMM, 1992, BIOT HEAD NOT APPL 2